. . . . . . "Carbamazine"@en . . . "Dietilcarbamazina"@en . . . . . . . . . . "approved"@en . " "@en . . . . "Di\u00E9thylcarbamazine"@en . "Parasitic nematodes and other roundworms"@en . "Camin"@en . . "Diethylcarbamazinum"@en . . . "Diethylcarbamazine"@en . . . "Humans and other mammals"@en . "Approximately 8 hours."@en . "Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori."@en . . . . . "90-89-1"@en . . . . "An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa. [PubChem]"@en . . . "Readily absorbed following oral administration."@en . "The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1."@en . . . . . . "Diethylcarbamazin"@en . . " "@en . "N,N-Diethyl-4-methyl-1-piperazinecarboxamide"@en . "Oral LD₅₀ in rat and mouse is 1400 mg/kg and 660 mg/kg, respectively."@en . . . . . . "Kushner, S. and Brancone, L.; US. Patent 2,467,893; April 19,1949; assigned to American Cyanamid Company. Kushner, S. and Brancone, L.; US. Patent 2,467,895; April 19, 1949; assigned to American Cyanamid Company."@en . . . .